Phase II Multicenter, Open‐Label Study of Oral ENMD‐2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma

LESSONS LEARNED: The fibrolamellar carcinoma‐associated DNAJB1‐PRKACA gene fusion transcript RNA codes for the catalytic domain of protein kinase A and, thus, overexpression of Aurora kinase A. ENMD‐2076 showed a favorable toxicity profile. The limited results, one patient (3%) with a partial respon...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Abou‐Alfa, Ghassan K., Mayer, Robert, Venook, Alan P., O'Neill, Allison F., Beg, Muhammad S., LaQuaglia, Michael, Kingham, Peter T., Kobos, Rachel, Basturk, Olca, Brennan, Cameron, Yopp, Adam, Harding, James J., Leong, Stephen, Crown, John, Hoti, Emir, Leonard, Gregory, Ly, Michele, Bradley, Mikaela, Valentino, Emily, Markowitz, David, Zukiwski, Alexander, Ren, Ken, Gordan, John D.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8186410/
https://ncbi.nlm.nih.gov/pubmed/32154962
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0093
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados